|
 |
Anti-CTGF -
HIF Cytoprotection -
HIF Anemia -
Collagen/Gelatin
Browne 2007 - A Targeted cDNA
Microarray Identifies Cytoskeletal Regulatory Proteins as Transcriptional
Targets of Connective Tissue Growth Factor (CTGF)/CCN2: Implications
for Diabetic Nephropathy.
Gaffney 2007 - FG-3019 modulates
CTGF-mediated mesangial cell adhesion and cytoskeletal signaling:
implications for anti-CTGF directed therapeutic intervention.
Peruzzi 2007 - Urinary
Connective Tissue Growth Factor (CTGF) Excretion in Patients with Renal
Allograft.
Nguyen 2007 - Plasma connective
tissue growth factor (CTGF; CCN-2) predicts end-stage renal disease and
mortality in type 1 diabetic nephropathy.
Adler 2006 - Dose-escalation
phase I study of FG-3019, anti-CTGF monoclonal antibody, in patients
with type 1/2 diabetes mellitus and microalbuminuria.
Jaffa 2005 - Elevated CTGF Levels
are an Independent Risk Marker of Diabetic Vascular Disease.
Langsetmo 2005 - Anti-CTGF
Antibody Therapy With FG-3019 Prevents Diabetes-induced Increase in
Vascular Complications in Streptozotocin (STZ) Treated Rats.
Usinger 2005 - FG-3019, a
Neutralizing CTGF Monoclonal Antibody, Provides Renal, Metabolic and
Cardio-Protective Effects in Obese Type 2 Diabetic Mice.
Qi 2004 - Connective Tissue Growth
Factor Differentially Mediates Transforming Growth Factorbeta1 Induced
Fibrogenesis and Immunomodulation.
Nieuwenhoven 2004 -
Beneficial Effect of Dual Blockade of the Renin-Angiotensin System (RAS)
on Urinary Connective Tissue Growth Factor (CTGF) in Type 2 Diabetic
Patients with Nephropathy.
Lopez 2004 - Connective Tissue
Growth Factor (CTGF) Activates Nuclear Factor-kB (NF-kB) in Tubulo
Epithelial Cells.
Roestenberg 2004 -
Connective Tissue Growth Factor (CTGF) Expression Level in Podocytes
Relates to Glomerular Basement Membrane (GBM) Thickening in STZ-Induced
Diabetes Mellitus.
Roestenberg 2004 -
Connective Tissue Growth Factor (CTGF) Plasma Levels Correlate with
Plasma Creatinine Levels in Patients with Type I Diabetes Mellitus
(DM).
Roestenberg 2004 -
Upregulation of Connective Tissue Growth Factor (CTGF) in Glomerular
Epithelial Cells of Mice with STZ-Induced Diabetes Mellitus.
Flyvbjerg 2004 - Long-Term
Renal Effects of a Neutralizing Connective Tissue Growth Factor (CTGF)-
Antibody in Obese Type 2 Diabetic Mice.
Wang 2004 - Amelioration of
Diabetic Nephropathy (DN) Induced by Renal Ischemia-Reperfusion (IR) in
Rats with Diabetes Mellitus (DM) by Treatment with FG-3019, a Monoclonal
Antibody Against Connective Tissue Growth Factor (CTGF).
Mageto 2004 - Safety and
Tolerability of Human Monoclonal Antibody FG-3019, Anti-Connective Tissue
Growth Factor, in Patients with Idiopathic Pulmonary Fibrosis.
Ito 2003 - Human Urinary CTGF (CCN2)
as a Predictor of Progression of Chronic Renal Diseases.
Mannon 2003 - Connective Tissue
Growth Factor (CTGF): A Biomarker of Chronic Allograft Nephropathy (CAN).
Leask 2000 - Control of CTGF
Expression by Fibroblasts: Role of IFNgamma, TNF-alpha and the
Proteasome.
Heyman 2007 - Activation of
Hypoxia Inducible Factors (HIF) Ameliorates Hypoxic Distal Tubular Injury
in the Isolated Perfused Rat Kidneys (IPK).
Bernhardt 2007 - Donor
Pre-treatment with a HIF Prolyl Hydroxylase Inhibitor Improves Function
and Increases Long-Term Graft survival in an Allogenic Rat Transplant
Model.
Wang 2006 - Renoprotective and
Therapeutic Efficacy of the HIF Prolyl Hydroxylase Inhibitor FG-4539 in
Experimental Ischemia-Reperfusion Induced Acute Kidney Injury.
Langsetmo 2006 - Inhibition of
HIF-Prolyl Hydroxylases with FG-4539 is Neuroprotective in a Mouse Model
of Permanent Focal Ischemia.
Guo 2004 - Improvement of Kidney
Function in a Rat Model of Renal Ischemia-Reperfusion Injury by Treatment
with a Novel HIF Prolyl Hydroxylase Inhibitor.
Nwogu 2000 - Inhibition of Collagen
Synthesis Improves Left Ventricular Function (LV) After Myocardial
Infarction (MI).
Frohna 2007 - Preliminary
Results from a Randomized, Single-Blind, Placebo-Controlled Trial of
FG-4592, a Novel Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor,
in Subjects with CKD Anemia.
Bernhardt 2007 - The
prolylhydroxylase inhibitor FG2216 stimulates EPO production in nephric
and anephric dialysis patients - evidence for an underutilized production
capacity in liver and kidneys.
Guo 2007 - HIF-PH Inhibitor,
FG-4592, Treats Anemia and Prevents Elevation of SBP in Uremic Rats.
Hsieh 2005 - Chronic Intermittent
Administration of HIF Prolyl Hydroxylase Inhibitor Significantly
Induces Erythropoietin and Increases Total Hemoglobin in Normal Rhesus
Macaques.
Günzler 2005 - FG-2216
Increases Hemoglobin Concentration in Anemic Patients with Chronic
Kidney Disease.
Wang 2005 - Induction of Renal
and Extra-Renal Erythropoietin Production by Orally Bioavailable HIF
Prolyl Hydroxylase Inhibitors.
Klaus 2005 - Induction of
Erythropoiesis and Iron Utilization by the HIF Prolyl Hydroxylase
Inhibitor FG-4592.
Langsetmo 2005 - FG-2216
Corrects Anemia and Improves Iron Utilization in a Rat Model of Anemia
of Chronic Disease: Comparison to Darbepoetin.
Seeley 2005 - FG-2216: Tumor
Progression Studies and Correction of Anemia of Chronic Disease in
Xenograft Models.
Liu 2005 - Novel and Beneficial
Pharmacodynamic Properties of Endogenous EPO and 'Complete Erythropoiesis'
Induced by Selective HIF Prolyl Hydroxylase Inhibitors.
Wang 2004 - Stimulation of
Erythropoiesis and Treatment of Anemia in Rodents by Oral Administration
of FG-2216, a Novel HIF-Prolyl Hydroxylase Inhibitor.
Langsetmo 2004 - Effect
of FG-2216 on Anemia and Iron Transport in a Rat Model of Anemia of
Chronic Disease.
Klaus 2004 - Novel Prolyl
Hydroxylase Inhibitors Overcome Inflammatory Cytokine-Mediated Suppression
of EPO Secretion.
Urquilla 2004 - Upregulation
of Endogenous EPO in Healthy Subjects by Inhibition of HIF-PH.
Urquilla 2004 - Upregulation
of Endogenous Erythropoietin (EPO) in Healthy Subjects by Inhibition of
Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase.
Yang C, Hillas P, Tang J, Balan J, Notbohm H, Polarek J.
Development of a recombinant human collagen-type III based hemostat.
J Biomed Mater Res. 2004 Apr 15;69B(1):18-24.
Yang C, Hillas PJ, Baez JA, Nokelainen M, Balan J, Tang J, Spiro
R, Polarek JW. The application of recombinant human collagen in
tissue engineering. BioDrugs. 2004;18(2):103-19.
Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, Carmichael
D, Perala M, Hamalainen ER, Jarvinen M, Polarek J. Recombinant
collagen and gelatin for drug delivery. Adv Drug Deliv Rev. 2003
Nov 28;55(12):1547-67.
Olsen 2003 - Development
of Recombinant Human Gelatin for Use as a Stabilizer in
Biopharmaceuticals.
Oulu 2002 - Plants as Factories
for Therapeutic Structural Proteins.
Helsinki 2002 - Plants as
Factories for Therapeutic Proteins.
Spiro 2002 - Recombinant Human
Collagens for Tissue Engineering Applications.
Baez 2001 - Use of Transgenic
Plants for the Production of Structural Proteins.
Baez 2001 - Characterization of
Hydroxylated Human Recombinant Collagen From Transgenic Systems.
Yang 2001 - Characterization of
Hydroxylated Collagen in Tobacco Cell Culture.
Ruangpanita 2001 - Gelatinase
A (MMP-2) activation by skin fibroblasts: dependence on MT1-MMP expression
and fibrillar collagen form.
McCombe 2000 - Inhibition of
the Fibroblasts of the Flexor Tendon and its Synovial Sheath Using a
New Prolyl Hydroxylase Inhibitor.
McGowan 2000 - BMP-1 Processing
of Laminin-5 Controls Migration of Human Epithelial Cells.
Olsen 2000 - Development
of Recombinant Human Gelatins and Specific Molecular Type Human
Gelatins.
Olsen 2000 - Expression and
Characterization of Recombinant Human Gelatin Fragments.
|
| |
